<DOC>
	<DOCNO>NCT02622334</DOCNO>
	<brief_summary>The purpose study assess safety , tolerability , IOP effect RO5093151 follow 7 day topical ocular treatment patient primary open angle glaucoma ocular hypertension .</brief_summary>
	<brief_title>A Study Investigate Safety , Tolerability , Pharmacokinetics , Pharmacodynamics RO5093151 Patients With Primary Open Angle Glaucoma ( POAG ) Ocular Hypertension ( OHT ) .</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Latanoprost</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Diagnosis ocular hypertension ( OHT ) primary open angle glaucoma ( POAG ) least one eye ( qualify eye ) determine Investigator screen base reliable documented assessment do within last 6 month prior screen provide progression visual field damage expect At baseline visit , intraocular pressure ( IOP ) &gt; = 24 mmHg morning &gt; = 21 mmHg afternoon measurement least one eye ( qualify eye = study eye ) = &lt; 34 mmHg time point eyes Best correct logMAR visual acuity score 0.7 ( 20/100 Snellen ) good eye measure ETDRS visual acuity test screen Central corneal pachymetry measurement 420 620 micrometer qualify eye screen Cuptodisk ratio = &lt; 0.8 ( eye ) screen Anterior chamber angle open nonoccludable confirm Investigator gonioscopy examination screen History clinically significant gastrointestinal , renal , hepatic , bronchopulmonary , neurological , psychiatric , cardiovascular , endocrinological , hematological allergic disease ( multiple allergy , seasonal allergy acceptable ) , metabolic disorder , cancer cirrhosis Uncontrolled hypertension ( SBP &gt; = 160 mmHg and/or DBP &gt; = 100 mmHg ) despite treatment time screen confirm average &gt; = 3 blood pressure measurement , properly measure wellmaintained equipment Clinically significant abnormality laboratory test result screen Hypersensitivity RO5093151 component formulation , hypersensitivity latanoprost component formulation ( Part B ) Donation blood 500 mL within three month prior screen Positive result hepatitis B ( HBV ) , hepatitis C ( HCV ) , HIV 1 2 Presence narrow angle ( = &lt; grade 2 Shaffer gonioscopic classification ) complete partial closure , measure gonioscopy risk angle closure assess Investigator Other form glaucoma POAG OHT study eye Any abnormality prevent reliable applanation tonometry Any clinically significant corneal scarring , haze opacity Patient uncooperativeness restricts adequate examination IOP , ocular fundus anterior chamber Evidence clinically significant blepharitis , concurrent infectious/noninfectious conjunctivitis , keratitis uveitis History sign penetrate ocular trauma . Uneventful ( uncomplicated ) cataract surgery perform 3 month prior screen allow According Investigator 's best judgment , risk visual field visual acuity worsen either eye consequence glaucoma progression consequence participation trial ( i.e. , washout ocular hypotensive medication treatment placebo ) ocular disease Unable safely stop ocular hypotension medication prior randomization accord require minimum washout period History ocular filter surgical intervention , previous glaucoma intraocular surgery , laser trabeculoplasty History refractive surgery ( laser assist insitu keratomileusis , laser epithelial keratomileusis , photorefractive keratectomy , phototherapeutic keratectomy ) Any intraocular surgery within 6 month screen Advanced agerelated macular degeneration ( wet dry ) , vitreous hemorrhage , diabetic retinopathy progressive retinal optic nerve disease cause glaucoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>